Capsule Summary Slidesets

Share

Program Content

Activities

  • CodeBreaK101: Sotorasib + RMC-4630
    CodeBreaK101: Phase Ib/II Study With Sotorasib + RMC-4630, an SHP2 Inhibitor, in Advanced NSCLC and Other Solid Tumors With KRAS p.G12C Mutation
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 12, 2022

    Expires: August 11, 2023

    View Activity
  • DeLLphi-300: Tarlatamab in SCLC
    DeLLphi-300: Updated Data From Phase I Study of Tarlatamab, a DLL3-Targeted T-Cell Engager, in Relapsed/Refractory SCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 12, 2022

    Expires: August 11, 2023

    View Activity
  • Second-Course Pembrolizumab in NSCLC
    Results of a Pooled Outcomes Analysis of Phase III Trials Using a Second Course of Pembrolizumab in Advanced NSCLC
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 16, 2022

    Expires: August 15, 2023

    View Activity
  • IMpower010: OS With Adjuvant Atezo in Early-Stage NSCLC
    IMpower010: Updated Data of Phase III Trial of Adjuvant Atezolizumab vs BSC in Resected Stage IB-IIIA NSCLC After Adjuvant Chemotherapy
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 16, 2022

    Expires: August 15, 2023

    View Activity
  • CodeBreaK100/101: Sotorasib + Atezo or Pembro
    CodeBreaK100/101: Phase Ib Report of Safety and Efficacy of Sotorasib + Atezolizumab or Pembrolizumab in Patients With Pretreated KRAS G12C–Mutated NSCLC
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 16, 2022

    Expires: August 15, 2023

    View Activity
  • Treatment Inequities in NSCLC
    Population-Based Assessment of Socioeconomic Treatment Inequities With Biomarker-Guided Targeted Therapy and Immunotherapy for Patients With NSCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 17, 2022

    Expires: August 16, 2023

    View Activity
  • NADIM II: Neoadjuvant Nivo + CT
    NADIM II: Survival Results From Phase II Study of Nivolumab + Chemotherapy vs Chemotherapy as Neoadjuvant Treatment for Resectable IIIA-B NSCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 18, 2022

    Expires: August 17, 2023

    View Activity
  • HUDSON Umbrella Study
    HUDSON: Open-Label, Multidrug Umbrella Phase II Study in Patients With Advanced NSCLC After Progression on PD-1/PD-L1 Inhibitor Therapy
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 18, 2022

    Expires: August 17, 2023

    View Activity
  • YESS: Personalized Smoking Cessation Support
    YESS: Effectiveness of Adding Colocated Personalized Smoking Cessation Support to a Lung Cancer Screening Program
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 18, 2022

    Expires: August 17, 2023

    View Activity
  • TROPION-Lung02: Dato-DXd + Pembro and CT
    TROPION-Lung02: Initial Results From Phase I Study of Datopotamab Deruxtecan + Pembrolizumab and Platinum Chemotherapy in Advanced NSCLC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 18, 2022

    Expires: August 17, 2023

    View Activity
  • CALGB 140503: Sub-Lobar Resection
    CALGB 140503 (Alliance): Phase III Trial of Lobar or Sublobar Resection for Peripheral Clinical Stage IA NSCLC With Tumor Size ≤2 cm
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 19, 2022

    Expires: August 18, 2023

    View Activity

Provided by

ProCE Banner

Supporters

Amgen, Inc.

Genentech, a member of the Roche Group

Merck Sharp & Dohme Corp.

Turning Point Therapeutics Inc